Professional Documents
Culture Documents
Scot M. Silverstein, MD
Assistant Professor of Healthcare Informatics and IT
Director, Institute for Healthcare Informatics
Drexel University, College of Information Science & Technology
(Former Director of Published Information Resources & The Merck Index, MRL)
Goals
• Promote better understanding of Medical Informatics as
a formal, cross-disciplinary clinical/IT specialty, lift veil
of mystery that leads to misuse of term.
• Raise awareness of national EMR initiatives on the
provider side, and how these may be increasingly
important to pharma in eClinical trials, post-marketing
surveillance and other needs.
• Raise awareness of difficulties in implementing large-
scale EMR, and how Medical Informatics professionals
can help (interestingly, analogous “sociotechnical” issues
are found in pharma).
The iSchools
Focus is on how people seek, use or interact with information using technology,
not simply on technologic devices and computer programs.
• University of California, BerkeleySchool of Information Management and Sy
stems University of MichiganThe School of Information
• University of California, Los AngelesGraduate School of Education and Infor The Pennsylvania State UniversitySchool of Information Scienc
mation Studies es and Technology
• Drexel UniversityCollege of Information Science and Technology University of PittsburghSchool of Information Sciences
• Florida State UniversityCollege of Information Rutgers, the State University of New JerseySchool of Communi
cation, Information, and Library Studies
• Georgia Institute of TechnologyCollege of Computing
– FDA lacks clear and effective processes for making decisions about, and providing
management oversight of, postmarket safety issues. The process has been limited by a lack
of clarity about how decisions are made and about organizational roles, insufficient
oversight by management, and data constraints … There are weaknesses in the different
types of data available to FDA, and FDA lacks authority to require certain studies and has
resource limitations for obtaining data. Some of FDA's initiatives, such as the
establishment of a Drug Safety Oversight Board, a draft policy on major postmarket
decision making, and the identification of new data sources, may improve the postmarket
safety decision-making process, but will not address all gaps … FDA is taking steps to
identify additional data sources, but data constraints remain [1].
• [1] “Drug Safety: Improvement Needed in FDA’s Postmarket Decision-making and Oversight Process”, United States Government
Accountability Office, Washington, D.C., March 2006, http://www.gao.gov/new.items/d06402.pdf , p. 5.
Gartner “Predicts 2006” document:
Life Science Manufacturers Adapt to Industry Transitions
http://www.gartner.com/DisplayDocument?doc_cd=134309
• The swift and severe judgment in favor of the plaintiff in the first Merck Vioxx trial sent a shock wave
through the biopharma industry. It shows that biopharma manufacturers must do more to ensure that
healthcare providers and the public have an accurate, ongoing assessment of medication risks. Biopharmas
must also ensure that information on these risks is communicated promptly in an open, understandable
manner. Posting clinical trial information on a web site is one step towards greater transparency, but does
not provide information in a way that [easily] enables ... comparisons of benefits and risks.
• ... It is still well recognized that all the possible side effects of a medication cannot be uncovered using
[only] a randomized sample of study subjects. The true test of [long-term] safety and efficacy can only be
determined when trial data is combined with other sources of information such as clinical encounters,
adverse events (MedWatch) or observational studies (National Registry of Myocardial Infarction).
• In the future, it is hoped that the EMR system will capture point-of-care information in a standardized
format that can be used for drug surveillance. Today, biopharmas must be content with these other
available, if imperfect, information stores.
Gartner Predicts 2006 (cont.)
• Biopharmas ... should look at risk from multiple perspectives ... they must also get
actively involved in defining the electronic health and medical record so that it
will contain the type of information required to make better safety assessments
in the future.
• Biopharmas that ignore the opportunity to use analytical tools to proactively review
contradictory sources of study information (for example, pre- and post-approval
clinical data sets, as well as registries) will miss essential signals regarding product
safety. Yet today, only a small percentage of biopharmas routinely utilize
personnel with medical informatics backgrounds to search for adverse events in
approved drugs.
Institute of Medicine weighs in
– [1] “The Future of Drug Safety: Promoting and Protecting the Health of the Public”, Committee on the
Assessment of the US Drug Safety System, Alina Baciu, Kathleen Stratton, Sheila P. Burke, Editors,
Board on Population Health and Public Health Practice (BPH), Institute of Medicine (IOM), 2006,
Recommendation 4.6, p. 104-105, http://fermat.nap.edu/books/0309103045/html/104.html
Institute of Medicine weighs in (cont.)
• In its new 2007 report “Preventing Medication Errors: Quality Chasm Series”, the
Committee on Identifying and Preventing Medication Errors of the Institute of
Medicine has written that:
– [1] “The Future of Drug Safety: Promoting and Protecting the Health of the Public”, Committee on the
Assessment of the US Drug Safety System, Alina Baciu, Kathleen Stratton, Sheila P. Burke, Editors,
Board on Population Health and Public Health Practice (BPH), Institute of Medicine (IOM), 2006,
Recommendation 4.6, p. 102, http://fermat.nap.edu/books/0309103045/html/102.html
What is Medical Informatics?
• Medical Informatics studies the organization of medical information from fine-grained levels
(e.g., biomedical data modeling) to macro levels (e.g., MedDRA, UMLS), the effective use,
management and dissemination of information using computer technology (e.g., EMR,
CDSS, CPOE), and the impact of such technology on medical research, education, and patient
care.
• Formal, NIH-sponsored field on which NIH has provided many millions of dollars in training
grants for ~ the last two decades.
• Has been nearly invisible to pharma for numerous reasons, largely due to misunderstanding of
the field. Unfortunate.
• e.g., My analysis in PIR ca. 2000 identified significant cheminformatics and biomedical
informatics gaps, and through innovative use of technology and compelling arguments we
increased funding and availability of targeted scientific information to MRL R&D at least
tenfold by late 2003 over averages kept since ~ 1989. eJournals /Alertlink/ SciFinder /
CrossFire etc.
The Informatics Subspecialties
NIH training programs in Medical Informatics
http://www.nlm.nih.gov/ep/GrantTrainInstitute.html
1-Harvard-MIT Division of Health Sciences & Technology, 2-Yale University, 3-Columbia University, 4-University of Pittsburgh, 5-
Johns Hopkins University, 6-Medical University of South Carolina, 7-Vanderbilt University, 8-Indiana University - Purdue University
at Indianapolis, 9-University of Wisconsin Madison,10-University of Minnesota Twin Cities, 11-University of Missouri Columbia,
12-Rice University, 13-University of Utah, 14-University of California Irvine, 15-University of California Los Angeles, 16-Stanford
University, 17-Oregon Health & Science University,18-University of Washington (training is provided by other universities via
internal funds as well).
Medical Informatics: What it is not
• The increasingly common use of awkward expressions like "informatics technology" to refer
to clinical information systems is an example of semantic blur. Medical informatics is a formal
field of study and a scientific discipline. Computers in medicine is not the equivalent of
medical informatics.
• Yet, position descriptions such as in these employments ads, with requirements for neither
clinical nor medical informatics training or experience, are often seen. From the Philadelphia
Inquirer:
– Medical informatics analyst. [Company name] seeks a Medical Informatics Analyst to support resource management
and medical affairs in their data analysis needs. Through downloading of MCS database, PC-based analysis of clinical
and clinically-relevant financial data will be performed. Qualifications: BA/BS in computer science or related
discipline, 3-5 years experience in PC-based data analysis of health care information, knowledge of SAS or similar
analysis software, knowledge of mainframe DB2 database architectures, working knowledge of CPT-4 and ICD-9-CM
coding."
– From an Internet biomedical employment service, Medzilla.com: [Company name] seeks a Director of Clinical
Informatics. Overall coordination of design specifications, implementation and support for all internet/browser based
systems. Assurance of continued, reliable and consistent resources and applications to all corporate personnel and
external users who may rely upon these systems. Documentation and control of said software systems including
package systems and license control if necessary. Provide ongoing maintenance oversight and management support for
said systems. Organize and train personnel, both internal and external, who will be using said products. Client contact
and development and assist Sales and Marketing as necessary in client presentations. Minimum of a BA. MBA
preferred.
Medical Informatics: what it is not
• Blur in usage of the term "medical informatics" is highly ironic. One major
area of study in medical informatics research is language (e.g., controlled
terminologies, computation linguistics) and data modeling.
• In applied efforts in that area, exhaustive attention to lexical and semantic
issues and intense thinking about precision and imprecision in language
have led to excellent tools such as the National Library of Medicine's
Unified Medical Language System. Now, it seems the medical informatics
field is often finding its own name used in an imprecise way.
• Imagine impact of similar difficulty with, say, Medicinal Chemistry…
Why is Medical Informatics Important to EMR and
other healthcare IT initiatives?
• A number of very expensive healthcare IT project difficulties and failures have
appeared in the literature in recent years in large part due to organizational
change resistance, internal political struggles, lack of expertise in IT
implementation processes most suitable for clinical environments, and other
sociotechnical issues.
– Cedars-Sinai Hospital in Los Angeles [Doctors pull plug on paperless system. American Medical News,
Feb. 17, 2003]
– Hospital of the University of Pennsylvania [Role of computerized physician order entry systems in
facilitating medication errors. Koppel et al., JAMA 2005;293(10):1197-203]
– VA hospital CoreFLS failure - $472 million [http://www.usmedicine.com/article.cfm?articleID=932&issueID=66]
– United Kingdom NHS initiative [Doctors fear £6bn IT project will be a fiasco. The Guardian, February 8,
2005. [http://society.guardian.co.uk/internet/story/0,8150,1407903,00.html]
– Others [website Sociotechnical Issues in Health IT: Common Examples of Health IT Failure]
– Pharma examples – CRISP project - In the 1990s, [pharma] struggled to erect a modernized clinical data
system known as CRISP (Clinical and Regulatory Information Strategic Program), a project that current and
former information systems workers came to regard as a $100 million loss. "This project ran into a lot of
problems," says one former manager who was involved near the beginning of the CRISP project.
[http://www.baselinemag.com/article2/0,1397,1608582,00.asp]
Why is Medical Informatics important? (cont.)
• Healthcare IT and its environment are core competence
• Recognition that organizations are simultaneously social (people, values,
norms, cultures) and technical (tools, equipment, technology). These
elements are deeply interdependent and interrelated. Good design and
implementation is not just a technology issue but also one of jointly
optimizing the combined sociotechnical systems.
• Medical Informatics training recognizes these issues and trains cross-
disciplinary specialists accordingly. Curriculum example:
– Fundamental of computer science
Medical language and terminology systems
Modeling of medical observations and data
Medical coding systems
Medical knowledge structures
Information organization and flows in medical practice
Quantitative models for medical decision making
Clinical decision support
Medical image processing
User interfaces and ergonomics in healthcare
Health information systems architecture
Security and confidentiality
Ethical and legal issues in electronic medical records
Organizational and sociological issues in clinical IT projects
Metrics and methods for evaluating healthcare information systems
Cost and investment issues in healthcare IT
National EMR Initiatives: U.S.
• Transforming Health Care: The President’s Health Information
Technology Plan
– http://www.whitehouse.gov/infocus/technology/economic_policy200404/chap3.html
– President Bush has outlined a plan to ensure that most Americans have
electronic health records within the next 10 years. The President believes that
better health information technology is essential to his vision of a health care
system that puts the needs and the values of the patient first and gives patients
information they need to make clinical and economic decisions – in
consultation with dedicated health care professionals.
• Office of the National Coordinator for Healthcare IT (ONCHIT)-
established April 2004
– http://www.hhs.gov/healthit/
National EMR Initiatives: U.K.
• National Programme for IT in the NHS (described as “the world’s biggest
government IT project”)
– http://www.connectingforhealth.nhs.uk/
– The National Programme for IT, delivered by the new Department of Health agency NHS Connecting
for Health, is bringing modern computer systems into the NHS to improve patient care and services.
Over the next ten years, the National Programme for IT will connect over 30,000 GPs in the U.K. to
almost 300 hospitals and give patients access to their personal health and care information,
transforming the way the NHS works.
• The infrastructure will include new components integrated into existing national
reporting databases:
– A centralized national database, called the NHS Care Record, to include all patient electronic health
records. This data will likely be useful for epidemiological studies and drug surveillance on a
national scale (!)
– A Patient Demographics Services operation that will act as an enterprise master patient index (EMPI)
for the entire country, based on the patient's NHS number, a national patient identifier, and
demographic and patient encounter information.
Pharma takes notice: Integrating Patient Information with Drug Development
Nov. 2005: “Merging Electronic Health Records & Electronic Data Capture: Integrating Patient
Information with Drug Development”
http://exlpharma.com/events/ev_brochure.php?ev_id=17
• Exploring the Opportunity for Collaboration with Drug & Device Firms in Accelerating IT Adoption by Hospitals &
Physicians: The government’s 10-year plan to automate healthcare information exchange by creating the National Healthcare
Information Network presents an undeniable opportunity to synchronize patient information with drug development and
increase the overall quality of patient care.
• Drug & device companies have been struggling for years to successfully and efficiently move away from paper data collection
towards electronic data capture and automated trials. Without a unifying body behind this push, data standards, interoperability
and infrastructure compatibility have not been achieved. By piggy-backing on this government-lead initiative to automate
healthcare, drug and device firms can reap the benefits of the increased efficiency IT adoption at the hospital and physician
level will offer and utilize this data for more streamlined drug development [and other uses – ed.]
• ExL Pharma’s Merging EHR & EDC Conference is the “first opportunity for drug & device firms to gather with hospitals,
physicians and vendors to discuss strategies for accelerating IT adoption and achieving cross-functional data interoperability to
streamline processes, improve communication and maximize patient care.”
KEYNOTE PRESENTATION
Improving Patient Care while Optimizing Efficiency: Outlining the Potential Benefits from Merging Patient Care and Drug Development Efforts
Barbara Tardiff, MD, MBA
Executive Director, Research Information Services, Clinical & Regulatory Information Services
MERCK & CO., INC.
HOSPITAL PERSPECTIVE: The Challenges and Limitation of Merging Electronic Health Information Robert N. Hotchkiss, MD
Director, Clinical Research
HOSPITAL FOR SPECIAL SURGERY
STANDARDIZATION EFFORTS: Interchange Standards: The Key to Linking Healthcare and Clinical Research Information Rebecca Kush, PhD, President, CDISC
Landen Bain, Healthcare Liaison, CDISC
Sue Dubman, Director of Applications for the Center of Bioinformatics, NCI
Upcoming DIA-sponsored conference
• “The Quest to Enable the Electronic Clinical Trial: Finding
Clarity in a Confusing World” (Dec. 2006,
http://www.diahome.org/product/11116/06029.pdf )
• Learning objectives:
– Discuss medical informatics opportunities to improve the benefit-risk
assessment of drugs
– Explain standard controlled terminology and its current and future use
– Summarize how changes in the drug development industry impact people and
processes
– Discuss how clinical research can help drive the adoption of healthcare IT
standards
– Describe how increasing data transparency can benefit the public interest
EMR for post-market surveillance: possible?
• Use of EMR for drug surveillance has begun to be studied. There have been exploratory studies on this
topic and related areas:
– Murff et. al. reviewed current methodologies for detection of clinical adverse events including electronic methods that
can detect events using coded data, free-text clinical narratives, or a combination of techniques [1]
– Gandhi et. al conducted a similar review specifically aligned to drug safety issues and believe computerized monitoring
for adverse drug events using rules or “triggers” is a high yield and relatively inexpensive strategy that should be
adopted by healthcare organizations [2].
– Nebeker et. al. described prospective daily reviews of EMR data performed by pharmacists as an effective way to
detect adverse drug events [3].
– Honigman et. al. reported on an automated, computer-based retrospective analysis for adverse drug events of one year
of data from an EMR, including records on over 23,000 patients. The conclusion was that computerized search
programs can detect adverse drug events in such data and that such detefction programs demonstrate “value added” for
the EMR [4].
– Efforts in using EMR’s for drug post-marketing surveillance can also serve as a test bed for identifying and resolving
issues in broader uses of national EMR of even greater significance, such as syndromic surveillance for early epidemic
detection or detection of chemical terrorism or bioterrorism. Syndromic surveillance refers to using health-related data
that precede diagnosis and signal a sufficient probability of a case or an outbreak to warrant further public health
response. Hegmann et. al. described a system to detect possible bioterrorist attacks during the 2002 Olympic Games
using an EMR-based bioterrorism surveillance system. The system implemented 50 different analyses that examine a
range of symptoms to detect and track infectious diseases [5].
• [1] “Detecting adverse events for patient safety research: a review of current methodologies”, Murff HJ, Patel VL, Hripcsak G, Bates DW, Journal of
Biomedical Informatics, 36(1-2):131-143, Feb-Apr 2003.
• [2] “Identifying drug safety issues: from research to practice”, Gandhi TK, Seger DL, Bates DW, International Journal for Quality in Health Care, 12(1):69-
76, Feb. 2000.
• [3] “High rates of adverse drug events in a highly computerized hospital”, Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF, Archives of Internal
Medicine 165 (10): 1111-1116, May 23 2005.
• [4] “Using computerized data to identify adverse drug events in outpatients.” J Am Med Inform Assoc. 2001 May-Jun;8(3):254-66.
• [5] “Computer model developed at U. Utah monitors bioterrorism”, Daily Utah Chronicle (U. Utah), Feb. 4, 2002
EMR for postmarket surveillance (cont.)
• Utilizing large quantities of EMR data, innovative statistical models and methods for analysis of extremely
large datasets (large number of observations or large number of dimensions), an active area of research,
will be necessary to supplement and replace more simplistic methodologies (e.g., adverse event frequency
comparisons) for leveraging EMR data. Research in computational statistics, for example, involves the
development of visualization and computationally intensive methods for mining large, non-
homogeneous, multi-dimensional datasets so as to discover knowledge in the data [1].
• Research has been done specifically in the application of data mining techniques in drug surveillance. The
authors of one study describe knowledge discovery in databases (KDD), a technique to detect potential
adverse drug events involving the selection of data variables and databases, data preprocessing, data
mining and data interpretation and utilization. They describe data mining as encompassing a number of
statistical techniques including cluster analysis, link analysis, deviation detection and “disproportionality”
assessment which can be utilized to determine the presence of and to assess the strength of adverse drug
event signals. The authors concluded that in view of the importance of adverse drug events and the
development of massive data storage systems and powerful computer systems, the use of data mining
techniques in knowledge discovery in medical databases is likely to be of increasing importance in
the process of drug surveillance as they are likely to be able to detect signals earlier than more common
methods currently in use [2].
1500
Methods
1000
Conclusion
500 206
We used our website, entitled “Sociotechnologic Issues in Clinical 166 132
It appears there is an ongoing interest in information about
Computing: Common Examples of Healthcare IT Failure”, online 0 healthcare IT difficulty among searchers of varied
since 1999, as a representative information resource. S earch E ngine Healthc are IT S ite Other Non Healthc are IT
demographics, as evidenced by searches on these issues and
S ite
– Computer experts per se have virtually no idea of the real problems of medical or even hospital practice, and
furthermore have consistently underestimated the complexity of the problems…in no cases can [building appropriate
clinical information systems] be done, simply because they have not been defined with the physician as the continuing
major contributor and user of the information.
• Nemeth & Cook: “Hiding in Plain Sight”, Journal of Biomedical Informatics 38 [2005], 262–263
– Just beneath the apparently smooth-running operations [of healthcare] is a complex, poorly bounded, conflicted,
highly variable, uncertain, and high-tempo work domain. The technical work that clinicians perform resolves these
complex and conflicting elements into a productive work domain. Occasional visitors to this setting see the smooth
surface that clinicians have created and remain unaware of the conflicts that lie beneath it. The technical work that
clinicians perform is hiding in plain sight. Those who know how to do research in this domain can see through the
smooth surface and understand its complex and challenging reality. Occasional visitors cannot fathom this demanding
work, much less create IT systems to support it.
• Wears & Berg: “Still Waiting for Godot”, JAMA Vol. 294 No. 2, July 13, 2005
– Throwing IT at a health care system to remedy high medication error rates will not be effective unless the
organizational reasons for those failures also are addressed. These reasons are hidden in the "messy details" of clinical
work: complexity; uncertainty; conflicting goals; gaps in supplies, procedures, and coordination; brittleness of tools
and organizational routines.
The often divergent goals of three main groups within a medical center
From Sittig DF, Sengupta S, al-Daig H, Payne TH, Pincetl P. The role of the information architect at King Faisal Specialist Hospital and Research Centre.
Proc Annu Symp Comput Appl Med Care. 1995;:756-60
The Three Stakeholder Groups in More Detail
Administration (purchasers)
• CEO
• COO
• CFO
• Gen Counsel
• Clin leaders
• CIO (SVP, COS,
• IT staff Dept. Chairs)
• Consultant • Clinicians
• Service Mgr.
Information Technology (implementers) Medicine (users)
Observed Drivers: Health System Administration
Chief Executive Officer (CEO) Institutional reputation
Board issues
Internal relationships
Financial issues
Chief Financial Officer (CFO) Up-front costs (capital & expense)
Secondary dollars (longer-term clinical
revenue/technologic expense)
“Return on investment”
Chief Operating Officer (COO) Skepticism
Operational changes (in processes)
Managerial control
Staffing
Costs
General Counsel Liability / litigation on:
Clinical issues
Information security
Observed Drivers: Information Technology (MIS)
• Clin leaders
• CIO (SVP, COS,
• IT staff Dept. Chairs)
• Consultant • Clinicians
• Service Mgr.
Information Technology Medicine
Medical Informatics as Intermediary
Administration
• CEO
• COO
• CFO
• Gen Counsel
MI
• Clin leaders
• CIO (SVP, COS,
• IT staff Dept. Chairs)
• Consultant • Clinicians
• Service Mgr.
Information Technology Medicine
The desirable dynamics
Administration
• CEO
• COO
• CFO
• Gen Counsel
MI
• Clin leaders
• CIO (SVP, COS,
• IT staff Dept. Chairs)
• Consultant • Clinicians
• Service Mgr.
Information Technology Medicine
Medical Informatics role